Veradermics (MANE) Income towards Parent Company (2025 - 2026)
Veradermics (MANE) reported Income towards Parent Company of -$27.2 million for Q1 2026, down 119.61% on a YoY basis from $138.8 million in Q1 2025, and down 119.61% quarter-over-quarter from -$12.4 million in Q1 2025.
Veradermics (MANE) Income towards Parent Company (2025 - 2026) Analysis & Trends
Veradermics has reported Income towards Parent Company for 2 years, with the latest figure at -$27.2 million in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company fell 119.61% year-over-year to -$27.2 million; the trailing twelve-month figure through Mar 2026 stood at -$39.6 million (changed N/A YoY), and the FY2025 full-year result was -$70.0 million, down 164.25% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$27.2 million, down from -$12.4 million in the prior quarter.
- The five-year high for Income towards Parent Company was -$12.4 million in Q1 2025, with the low at -$27.2 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Veradermics | 2.13 Bn | 2.13 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.23 Mn |
| Mar 31, 2025 | -12.40 Mn |